Our Medical AI Solutions

BrainGML®-AD is proprietary software developed by GeodAisics that uses a 3D T1 MRI to analyse the cerebral atrophy profile and support the early detection of Alzheimer’s disease.

This software uses patient autopsy findings as its validation basis, while also taking into account biomarker values from the associated lumbar puncture.

Results are delivered to the radiologist within minutes as a three-category interpretation: Alzheimer’s similarity, indeterminate, or no Alzheimer’s similarity. An hourglass also shows the position of the analysed patient relative to the software’s validation population.

BrainGML®-AD can be used from the first MRI performed for cognitive complaints in patients aged 45 to 89. This software is currently undergoing Class IIa CE marking.

BioGML®-Advisor secures every laboratory test order before it is submitted: no missed tests, no unnecessary tests, and no delayed diagnoses. Medical intelligence integrates seamlessly into everyday tools and recommends the appropriate adjustments in real time, with sources and justification, without ever fabricating information.

It also identifies what no rule can yet detect: signs of rare or silent diseases hidden within apparently normal results.

The physician always retains the final decision; the technology simply provides faster and deeper insights. The result: earlier diagnoses, fewer unnecessary costs, and safer care for patients. This expertise has already been proven across hundreds of analytes and thousands of clinical situations.

BrainGML®-MS translates brain MRI into clear information for therapeutic decision-making in multiple sclerosis. Where conventional imaging may show only a stable lesion, our AI reveals deeper changes — brain atrophy and chronic inflammation — through two simple, explainable scores, validated with over 95% accuracy and published in a leading scientific journal.

These objective data help specialists address key questions: whether to use a high-efficacy treatment from the outset, intervene early in high-risk cases, or adjust a treatment that appears insufficient. BrainGML®-MS is a research tool intended for interpretation by a specialist. It supports medical decision-making without ever replacing it.

OtoGML® transforms a 3D T2 MRI scan into a precision tool for the surgery and prognosis of vestibular disorders. Before cochlear implantation, it automatically measures the cochlea to adapt the choice and positioning of the implant to the patient’s anatomy, supporting safer surgery and better hearing outcomes.

Using the same imaging data, OtoGML® detects early signs of bilateral progression in Ménière’s disease and helps guide patient management even before consultation with a specialist.

In patients with genetic inner-ear disorders, particularly Pendred syndrome, it also provides strong diagnostic and prognostic performance for vestibular function.

A single MRI sequence therefore provides several benefits: greater precision in the operating room and in the management of vestibular and cochlear disorders, without any additional examination or burden for the patient.